Inhibitors | Comment | Organism | Structure |
---|---|---|---|
1-methyl-DL-tryptophan | - |
Homo sapiens |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|
Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|
45000 | - |
x * 45000 | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
lymphocyte | - |
Homo sapiens | - |
Subunits | Comment | Organism |
---|---|---|
? | x * 45000 | Homo sapiens |
Synonyms | Comment | Organism |
---|---|---|
IDO | - |
Homo sapiens |
General Information | Comment | Organism |
---|---|---|
malfunction | hemodialysis patients characterized by impaired adaptive immunity, exhibit increased IDO expression, further enhanced in the non-responders to hepatitis B virus vaccination | Homo sapiens |
metabolism | indoleamine 2,3-dioxygenase catalyses the initial rate-limiting step of tryptophan degradation along the kynurenine pathway | Homo sapiens |
physiological function | indoleamine 2,3-dioxygenase suppresses adaptive immunity. It induces T-cell differentiation to regulatory T-cells through tryptophan depletion and/or kynurenine pathway products. The enzyme decreases glucose uptake by stimulated lymphocytes, increases mitochondrial function in stimulated lymphocytes, decreases aerobic glycolysis in stimulated lymphocytes, and induces the production of the immunosuppressive cytokine IL-10 by stimulated lymphocytes. Effect of IDO on glucose metabolism of lymphocytes, overview | Homo sapiens |